# Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125

> **NCT03185195** · PHASE1 · COMPLETED · sponsor: **Aquinox Pharmaceuticals (Canada) Inc.** · enrollment: 9 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** AQX-1125 Oral Tablet
- **DRUG:** [14C]-AQX-1125 IV
- **DRUG:** [14C]-AQX-1125 Oral Solution

## Key facts

- **NCT ID:** NCT03185195
- **Lead sponsor:** Aquinox Pharmaceuticals (Canada) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-22
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-01-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03185195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03185195, "Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03185195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*